Dublin, July 10, 2025 (GLOBE NEWSWIRE) -- The "PD-1 and PD-L1 Inhibitors Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The global PD-1 and PD-L1 ...

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025" has been added to ResearchAndMarkets.com's offering. The "PD-1 and PD-L1 Inhibitors - Competitive ...

Envafolimab plus docetaxel in combination with or without trilaciclib versus docetaxel in pretreated advanced or metastatic non-small cell lung cancer (NSCLC): Preliminary analysis of an open-label, ...

Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched ...

The FDA approved belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following treatment with a PD-1 or PD-L1 inhibitor.The combination ...

A novel treatment approach combining neoadjuvant immunotherapy with chemoradiation showed promising results in patients with locally advanced esophageal squamous cell carcinoma (ESCC), according to ...

The collaboration seeks to bring affordable cancer treatments to the region while advancing the ambitious Saudi Vision 2030.

Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven ...